It might depend on the proportion of the classical types in each trial. But given the phase 2 trial results I would guess maybe an 85% chance of success for the Lucentis trial and 65% chance for the Eyelea one. ASX continuous disclosure obligations should mean each trial is reported when the results come to hand.
It might depend on the proportion of the classical types in each...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
0.030(6.12%) |
Mkt cap ! $344.6M | |||
| Open | High | Low | Value | Volume |
| 48.5¢ | 52.0¢ | 48.3¢ | $273.6K | 546.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 47051 | 50.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.0¢ | 16084 | 2 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
51.8¢ |
Change
0.030 ( 4.86 %) |
||||
| Open | High | Low | Volume | ||
| 48.5¢ | 52.0¢ | 48.5¢ | 102223 | ||
| Last updated 15.59pm 05/06/2024 ? | |||||
| OPT (ASX) Chart |